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RESEARCH ARTICLE
Adding a temporal dimension to the study of Friedreich’s ataxia:
the effect of frataxin overexpression in a human cell model
Tommaso Vannocci1, Roberto Notario Manzano1, Ombretta Beccalli2, Barbara Bettegazzi2, Fabio Grohovaz2,
Gianfelice Cinque3, Antonio de Riso4, Luca Quaroni5, Franca Codazzi2 and Annalisa Pastore1,6,*
ABSTRACT
The neurodegenerative disease Friedreich’s ataxia is caused by
lower than normal levels of frataxin, an important protein involved in
iron–sulfur (Fe-S) cluster biogenesis. An important step in designing
strategies to treat this disease is to understand whether increasing the
frataxin levels by gene therapy would simply be beneficial or
detrimental, because previous studies, mostly based on animal
models, have reported conflicting results. Here, we have exploited an
inducible model, which we developed using the CRISPR/Cas9
methodology, to study the effects of frataxin overexpression in
human cells and monitor how the system recovers after
overexpression. Using new tools, which range from high-throughput
microscopy to in cell infrared, we prove that overexpression of the
frataxin gene affects the cellular metabolism. It also leads to a
significant increase of oxidative stress and labile iron pool levels.
These cellular alterations are similar to those observed when the
gene is partly silenced, as occurs in Friedreich’s ataxia patients. Our
data suggest that the levels of frataxin must be tightly regulated and
fine-tuned, with any imbalance leading to oxidative stress and toxicity.
KEY WORDS: Frataxin, Friedreich’s ataxia, Overexpression,
Oxidative stress
INTRODUCTION
Friedreich’s ataxia (FRDA) is a recessive, autosomal disease, with an
incidence of 1 in 50,000 individuals in Caucasians (Cossee et al.,
1997), characterized by progressive degeneration of large sensory
neurons and cardiomyopathies (Pandolfo, 2009). It is caused by the
expansion of a GAA triplet in the first intron of the FXN gene, which
results, through epigenetic modifications upstream of the gene, in
partial silencing of the gene product, frataxin, a mitochondrial protein
involved in the regulation of iron–sulfur (Fe-S) cluster biogenesis
(Pastore and Puccio, 2013; Sandi et al., 2013). Disease onset usually
occurs at <25 years of age and shows a roughly inverse correlation
with the length of the GAA expansion (Cossee et al., 1997). Typical
FRDA hallmarks include mitochondrial iron accumulation, increased
oxidative stress and abnormalities in Fe-S cluster biogenesis
(Pandolfo and Pastore, 2009), an essential pathway involved in fold
stabilization and/or providing electrons to cellular reactions.
Friedreich’s ataxia is currently incurable, but several independent
lines of research are being explored. Until a few years ago, the
only possible palliative treatment was idebenone, an antioxidant
preferentially used because of its ability to cross the mitochondrial
membrane more efficiently than other less expensive antioxidants,
such as vitamins C and E. Another more recent route consists of
importing frataxin fused to the endocytotic TAT signal directly in the
cell (Vyas et al., 2012). Although potentially attractive, this route
seems to be highly inefficient, because the level of the imported
protein is too low. The possibility of blocking frataxin degradation by
the proteasome, interfering with the normal process of programmed
cell death, was also proposed (Rufini et al., 2015). Finally, HDAC
inhibitors have been considered as an effective strategy to block
gene silencing. This promising direction was boosted by the
development of an inhibitor that is nontoxic for the cell compared
with other well-known compounds (Codazzi et al., 2016; Herman
et al., 2006; Rai et al., 2010). However, although careful screening
of HDAC inhibitors can be used to find the ones with lower
toxicity, the intrinsic nonspecific activity of these compounds can
lead to undesirable side effects on the transcription and regulation
of other genes.
An important ‘if’ in all these different strategies is understanding
what levels of frataxin are necessary to a healthy individual. Lack of
frataxin is certainly lethal, as shown by mouse knockout models,
which die at the embryonic stage (Cossee, 2000). FRDApatients have
reduced but variable frataxin concentrations, and symptoms start
appearing only when the frataxin level is <30% that of healthy
controls (Campuzano et al., 1996). On the opposite front, experiments
carried out in different cell and animal models in which frataxin was
upregulated have produced conflicting results; they can be divided
broadly into studies showing a harmless effect or even positive effects
of frataxin overexpression (Miranda et al., 2004; Runko et al., 2008;
Shoichet et al., 2002), especially in the cyto-protection from oxidative
stress, and studies showing that frataxin overexpression has a
detrimental effect on Fe-S biogenesis and increases oxidative stress
(Llorens et al., 2007; Navarro et al., 2011; Seguin et al., 2009).
Preliminary evidence also suggests that frataxin overexpression is as
toxic as its partial depletion (Navarro et al., 2011). It was also reported
that frataxin overexpression in a mammalian cell model is able
to activate oxidative phosphorylation (OXPHOS), boost ATP
production and increase mitochondrial respiration (Ristow et al.,
2000). Another study based on yeast (Schizosaccharomyces pombe)
showed that mild overexpression of the frataxin homologue Fxn1
slightly increases the oxygen consumption rate (OCR), whereas high
levels of overexpression produce an 80% decrease in OCR (Wang
et al., 2014). Additionally, complexes I–III in the electron transportReceived 25 October 2017; Accepted 8 May 2018
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chain (ETC) contain Fe-S clusters, the activity of which could be
affected by frataxin-related disruption of Fe-S cluster biogenesis.
These studies are in agreement with the model in which frataxin
functions as a regulator of iron–sulfur cluster biogenesis, inhibiting in
prokaryotes and activating in eukaryotes the process of conversion of
cysteine into alanine through interaction with the desulfurase central
to the pathway (Pastore and Puccio, 2013).
Here, we again addressed the question of which effects frataxin
overexpression has on cellular metabolism using our mammalian
cell line (HEK-cFXN), which can produce different frataxin levels
by switching off the FXN gene (Vannocci et al., 2015). HEK-cFXN
was genetically engineered by producing knockout of the
endogenous FXN gene of HEK293 cells via CRISPR/Cas9
methodology and the integration in the genome of the inducible
cFXN cassette. This system, which is the first after the exploratory
study by Ristow et al. (2000) to use mammalian cells, allowed us not
only to overexpress frataxin but also to introduce a temporal
dimension; we monitored whether the cell recovers and how long is
required for recovery from overexpression when this is removed.
This information might be relevant in the development of
therapeutic studies with the aim of artificially boosting the
frataxin levels discontinuously. We used traditional methods and
new advanced methodologies that include fluorescence and in cell
infrared (IR). We show that frataxin overexpression is detrimental
for the cell, with an appreciable increase of the reactive oxygen
species (ROS) and labile iron pool (LIP) content. Partial recovery is
obtained only ∼1 week after removing overexpression. Our results
support a role of the protein as a regulator.
RESULTS
Cell model characterization
The HEK-cFXN cellular model that we developed is characterized
by a biallelic knockout of the endogenous FXN gene and by the
presence of an exogenous, inducible cDNA FXN cassette (cFXN).
The cFXN gene is under the control of CMV-TetO2, a tetracycline-
regulated promoter, and the exogenous protein that is expressed
carries at its C-terminus a 3x FLAG tag. The CMV-TetO2 promoter
thus allows us to switch the frataxin gene on and off and to induce
increasing levels of the protein as a function of the tetracycline
concentration (Vannocci et al., 2015). When HEK-cFXN cells
were treated with tetracycline (10 or 100 ng ml−1), frataxin
expression significantly increased (∼13- and 17-fold increase,
respectively) compared with the endogenous frataxin levels in wild-
type HEK293 cells. Removal of tetracycline caused a progressive
reduction of frataxin levels over an 8 day period, until physiological
levels were reached at day 8 (Fig. 1).
Frataxin overexpression and aconitase activity
Although the initiation of the disease is still under debate
(Pastore and Adinolfi, 2014), loss of Fe-S proteins has been
widely reported as being one of the hallmarks of FRDA. Notably,
reduction of aconitase activity, an important tricarboxylic acid cycle
enzyme, has been consistently associated with the silencing of the
FXN gene (Moreno-Cermeño et al., 2010; Poburski et al., 2016;
Rötig et al., 1997). As a marker for the loss of Fe-S proteins, we
tested the effects of overexpression of frataxin on the activity of
aconitase over time. The enzyme contains a [4Fe-4S]2+ ion, which
can be inactivated to a [3Fe-4S]+ cluster and catalyses the
conversion of citrate to isocitrate in the citric acid cycle. In vitro,
the reaction is moved towards an equilibrium between citrate and
isocitrate, passing through the intermediate cis-aconitate in the
presence of an excess of isocitrate. Aconitase activity, therefore, can
be monitored by following the increase in absorbance at 240 nm
associated with the formation of cis-aconitate. HEK-cFXN cells
were initially cultured in the presence of 10 ng ml−1 tetracycline.
The experiment was carried out by removing the antibiotic and
collecting cell samples at 0, 2, 4, 6 and 8 days to monitor not only
the effects of overexpression but also of its removal. In these
conditions, we monitored the effect of frataxin overexpression,
which returns gradually to approximately basal levels. The results
showed no significant effects on the aconitase activity when the
cells were cultured in the presence of tetracycline (overexpression)
Fig. 1. FXN expression of the new model system. The two graphs represent FXN expression in the presence of tetracycline (Tet) 10 and 100 ng ml−1,
respectively [histograms corresponding to 0 days without (w/o) Tet], or after Tet removal for the indicated number of days (2, 4, 6, 8 days w/o Tet). The progressive
reduction of FXN reached endogenous levels at day 8 without Tet. FXN expression was quantified (from three experiments) as folds over the endogenous FXN
level in HEK293 cells (HEKWT). Datawere analyzed by one-way ANOVA followed by Dunnett’s post hoc test. **P≤0.01. Representativewestern blots of FXN and
calnexin (as the loading control) are shown in the bottom panels.
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when compared with the activity measured in samples obtained
8 days after tetracycline removal (basal level of FXN expression;
Fig. 2). Any possible effect of tetracycline on aconitase activity was
excluded by performing the assay on HEK293 wild-type cells
treated with either 10 or 100 ng ml−1 tetracycline (Fig. S1).
These results indicate that overexpression does not affect
the aconitase levels compared with the control value (sample
at 8 days).
Overexpression affects mitochondrial function
We then assessed the mitochondrial function using the Seahorse
XF technology (mito stress test; Agilent), an instrument which
can measure OCR directly in living cells. In association with
three different compounds [oligomycin, carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP), and a mixture of
rotenone and antimycin A] that are added sequentially to the
medium, the measured variation in OCR can be used to assess the
state of several mitochondrial functions, such as basal respiration,
ATP production, maximal respiration and nonmitochondrial
respiration. The mitochondrial function of HEK-cFXN cells was
measured in cFXN overexpression conditions (10 or 100 ng ml−1
tetracycline) and monitored in a time-resolved way at 2, 4, 6 and
8 days on cells grown after removal of tetracycline (Fig. 3).
All OCR data were normalized using the values obtained from
the 8 day sample (basal level of FXN expression). In contrast to
the results obtained by Ristow et al. (2000), our study did not
show any beneficial effect of frataxin overexpression on
ATP production or on the levels of mitochondrial respiration.
We observed a significant reduction in basal respiration, ATP
production and maximal respiration for cells grown in the presence
of 100 ng ml−1 tetracycline (strong overexpression of cFXN). No
differences were obtained on cells grown with 10 ng ml−1
tetracycline or when exploring the reduction of frataxin levels
as a function of time. Any possible effect of tetracycline on
mitochondrial function was excluded by performing the Seahorse
assay on HEK293 wild-type cells treated with either 10 or
100 ng ml−1 tetracycline (Fig. S2). These results indicate that
overexpression of frataxin does not confer any beneficial
advantage to mitochondrial function.
Frataxin overexpression strongly affects oxidative stress
and iron content
The effects of frataxin overexpression on ROS generation and LIP
levels were analyzed in the culture conditions described above, i.e.
cells maintained for the indicated number of days in the absence of
10 ng ml−1 tetracycline. Frataxin expression was evaluated by
western blots in parallel with ROS and LIP at the same time points.
Measurements of ROS were performed not only in untreated cells,
but also under oxidative conditions to mimic the oxidative status
chronically present in patients. For this purpose, the cells were
subjected to a protocol of mild chronic iron overload (maintained
overnight in the presence of 50 μM of ferric iron) in combination
with acute administration of hydrogen peroxide (300 μM, 15 min).
ROS generation, studied either in the absence or in the presence of
hydrogen peroxide, promotes the oxidation of CellROX dye, the
fluorescence of which is proportional to the oxidation levels. All
data were normalized for fluorescence signals obtained at day 8,
when both frataxin expression and ROS levels are the lowest, to
highlight the effect of cFXN overexpression on ROS production.
This analysis shows a progressive and significant decrease of ROS
levels (Fig. 4A) that is directly correlated with frataxin expression
(see western blot inset in the upper panel). Frataxin overexpression
makes the cells particularly susceptible to oxidative conditions;
of note, the ROS levels were also higher in untreated cells,
suggesting that frataxin overexpression promotes oxidative stress
per se. ROS production was not affected by simple tetracycline
treatment, because wild-type HEK293 cells grown in the presence
or in the absence of the antibiotic (10 ng ml−1) showed the same
ROS levels, even after acute treatment with hydrogen peroxide
(300 μM, 15 min; Fig. 4B).
Alterations of frataxin expression might affect iron homeostasis,
not only at the mitochondrial level but also at the cytosolic level, with
potential consequences on oxidative stress. Therefore, the effects of
frataxin overexpression on LIP content were analyzed, by the calcein
fluorescent dye, at the same time points as ROS measurements.
Experiments were performed in the same conditions of mild iron
overload, because the sensitivity of the assaymakes themeasurements
of basal LIP unreliable (not shown). Interestingly, in these conditions,
LIP was significantly higher in cells overexpressing frataxin (0 and
2 days without tetracycline), indicating their reduced competence in
the control of cellular iron handling (Fig. 4C). Comparable results, in
terms of ROS production and LIP levels, were obtainedwhen the cells
were maintained in 100 ng ml−1 of tetracycline (data not shown).
We can therefore conclude that frataxin overexpression promotes
oxidative stress and alteration of cellular iron homeostasis.
In cell IR spectroscopy indicates strong metabolic changes
We measured the in cell IR absorption spectra at the same time
points. The average IR spectra were normalized to the band at
1545 cm−1. In a fixed cell, absorbance in this position is
commonly attributed to amide bonds, for example peptide
bonds and some amino acid side-chains, but also acetylated
polysaccharides (Arrondo and Goñi, 1999; Barth, 2000). In a live
sample, absorption bands from some metabolites also provide a
contribution to the absorption at this frequency (Quaroni and
Zlateva, 2014). It is commonly accepted, although not always
verified, that the contribution from proteins is dominant. The
strongest variations over time were observed for a doublet of sharp
bands at 2925 and 2853 cm−1 (Fig. 5A), which can be assigned
to long alkyl chains, such as the acyl chains of phospholipids
and triglycerides. Variations of the phospholipid content are also
supported by variations at 1743 and 1718 cm−1 (not shown),
Fig. 2. Overexpression does not affect aconitase activity. Results were
pooled from three independent experiments done in duplicates and are
expressed as means (±s.d.). Data were analyzed by ANOVA and Dunnett’s
post hoc test.
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which correspond to the bands of carbonyl groups of esters and
protonated carboxylic acids. A complex series of changes was also
observed in the 1000–1600 cm−1 range (Fig. 5B).
Given that band assignment in this region is complex in live cell
samples because of the presence of multiple and overlapping
bands, we carried out a correlated cellular microscopy (CSM)
analysis. CSM relies on two-dimensional correlation spectroscopy
(2DCOS) (Quaroni and Zlateva, 2014; Quaroni et al., 2011) to
assign complex band patterns in cellular spectra that evolve over
time, based on the correlation of their changes. The bands that
evolve in synchrony are clustered together (Fig. S3). CSM allowed
us to identify two main groups of bands that change as a function
of time (Fig. 5B). One set corresponds to the absorption bands of
phospholipids (1084, 1174, 1225, 1375 and 1460 cm−1), together
with other molecules that are likely to be carboxylate- or alkyl
ammonium-containing molecules, including metabolites and
amino acid side-chains (1542, 1575 and 1585 cm−1). This can
be interpreted as a change in the lipid to protein ratio. Interestingly,
an altered lipid to protein ratio was already reported in both
Drosophila and mouse FRDA models (Chen et al., 2016a,b;
Martelli et al., 2012; Navarro et al., 2010). Changes in the opposite
direction of another set of bands (1028, 1098, 1105, 1125, 1155,
1248, 1355, 1402, 1435 and 1480 cm−1) are assigned to the
combined contribution of several molecules, such as metabolites
(Quaroni and Zlateva, 2014; Quaroni et al., 2016). The changes
indicate major variations in cellular metabolism and suggest an
overall alteration of the protein to phospholipid ratio.
The effect occurs during the first 2 days after tetracycline
removal. It then returns to the initial value (time 0) around day 6
and increases thereafter. The changes cannot be ascribed only to
differences in frataxin levels; comparison of the average spectra of
cell cultures grown with different levels of frataxin overexpression
(10 or 100 ng ml−1 of tetracycline) show only minimal differences
(Fig. S4), as expected from the relative contribution of frataxin to the
total proteome. We can interpret these results as an initial change in
overall protein expression, which is then compensated by activation
of different pathways over the next 2 days, leading to renewed rates
of protein synthesis. These experiments thus reveal as yet
unidentified aspects of imbalances of the frataxin levels.
DISCUSSION
Here, we have studied the effects of different frataxin levels in a
cellular model. This knowledge is needed to understand how to fine-
tune the protein levels during the development of therapies that
could be used for the treatment of FRDA. We probed different
cellular functions using different advanced techniques and
monitoring the temporal progression towards physiological levels
of frataxin. We found that strong overexpression of frataxin does not
confer any beneficial advantage on mitochondrial function. On the
contrary, a strong overexpression (100 ng ml−1 tetracycline) leads to
a significant reduction in ATP production and basal and maximal
respiration. The negative effects of cFXN overexpression are even
more striking on oxidative stress and LIP. Iron dysregulation
was observed solely in conditions of highly elevated frataxin
Fig. 3. Mitochondrial function was
monitored for different levels of
overexpression (10 and 100 ng ml−1
tetracycline) and in a time-resolved way at
0, 2, 4, 6 and 8 days on cells grown after
removal of tetracycline. The mitochondrial
stress test was performed by measuring
OCR variations of cells. Basal respiration,
ATP production, maximal respiration and
nonmitochondrial respiration were obtained
by sequentially treating the samples with
oligomycin, FCCP and rotenone/antimycin A
compounds. Results are expressed as
means (±s.d.) from five independent
experiments, each with 12 technical
replicates (4×104 cells per sample). The
recorded signals were normalized against
total protein content. Data were analyzed by
ANOVA and Dunnett’s post hoc test.
****P≤0.0001, **P≤0.01.
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overexpression, in which the mild alterations in mitochondrial
function could hardly be the cause. LIP elevation can, at least in
part, account for the generation of oxidative stress, although ROS
production also remains elevated when LIP returns to the basal level,
suggesting that other mechanisms might be involved, as proposed
below. Finally, we have also proved the feasibility of studies based on
new and complementary techniques, such as in cell IR.
It is appropriate to compare our results with those obtained using
other animal and/or cellular models. The first similar study dates
back to 2000, when Ristow et al. (2000) showed that frataxin
overexpression in mammalian cells causes a calcium-induced
upregulation of tricarboxylic acid cycle flux and respiration,
which results in an increased mitochondrial membrane potential
and an increase of cellular ATP levels. The authors concluded that
frataxin plays an important role in mitochondrial energy conversion
and oxidative phosphorylation. Seguin et al. (2009) looked at
different aspects in a Saccharomyces cerevisiae model. They
showed that mitochondrial iron is more available to ferrochelatase in
frataxin-overexpressing yeast, resulting in higher levels of haem
synthesis in vitro. They also showed that overexpression results in a
shift from frataxin trimers to oligomers of higher molecular mass in
the mitochondrial matrix and that, surprisingly, the overexpressed
cells are more resistant to oxidizing agents than wild-type
cells (Seguin et al., 2009). Runko et al. (2008) showed that
overexpression of frataxin in Drosophila increases antioxidant
capability and resistance to oxidative stress insults and results in
longevity. These results suggest that Drosophila frataxin might
function as a factor that protects mitochondria from oxidative stress
and cellular damage.
Navarro et al. (2011) obtained transgenic Drosophila flies that
overexpressed human or fly frataxin using the UAS-GAL4 system.
The authors observed deleterious effects at the biochemical,
histological and behavioural levels for both model systems and
increased levels of oxidative stress. They also proved that frataxin
overexpression reduces Drosophila viability and impairs the normal
embryonic development ofmuscle and the peripheral nervous system,
with reduced levels of aconitase activity. Frataxin overexpression in
the nervous system reduces lifespan, impairs locomotor ability and
causes brain degeneration (Navarro et al., 2011).Most recently,Wang
et al. (2014) showed that overexpression of the frataxin homologue
fxn1 under a thiamine repressible promoter in an S. pombe model
results in a phenotype strongly dependent on the amount of Fxn1
overexpression. They showed that high Fxn1 overexpression
inhibits S. pombe growth and impairs mitochondrial membrane
integrity and cellular respiration. It also leads to Fxn1 aggregation
and cellular iron accumulation. Defence mechanisms against
oxidative stress and mitochondrial Fe-S cluster-containing enzyme
activities proved to be upregulated upon overexpression. The
authors concluded that dysregulated Fe-S cluster biogenesis is a
primary effect that is shared by both frataxin overexpression and
deficiency (Wang et al., 2014).
The discrepancies between these results could be rationalized by
considering that the animal models used in these studies are very
different, as are the methodologies and the assays. Overall, our data
represent the only example, after the work of Ristow et al. (2000) in
the very early days of investigation of frataxin, from mammalian
cells. Nevertheless, contrary to this previous study, we do not find
that frataxin overexpression results in a significant increase in ATP.
We show that mitochondrial function is differently affected by
increasing levels of FXN overexpression; therefore, the discrepancy
could be attributable to differences in the levels of FXN
overexpression achieved in the two models. It is also possible that
Fig. 4. HEK-cFXN cells show a correlation among ROS levels, LIP and
frataxin expression. (A) The two graphs represent ROS levels analyzed
concomitantly on HEK-cFXN maintained under the indicated conditions and
normalized for the lowest value [in untreated cells, kept 8 days without
tetracycline (Tet; dashed line)]. The inset in the left panel represents the
expression of frataxin at the corresponding time points of Tet deprivation.
Oxidative conditions were obtained by overnight treatment with ferric iron
(50 μM ferric ammonium citrate) combined with acute exposure to hydrogen
peroxide (15 min, 300 μM). The bars correspond to the mean (±s.e.m.),
from three independent experiments (each condition in duplicate; >5000 cells
per condition), of CellROX fluorescence signals. Representative
fluorescence images from the time points indicated by the arrows are shown
in the lower panel. Statistical significance was calculated using one-way
ANOVA followed by Dunnett’s post hoc test; *P<0.05, **P<0.01. (B) ROS
levels, analyzed in wild-type HEK293 (HEK293 WT) were not affected by Tet
(10 ng ml−1) treatment, even after hydrogen peroxide (15 min, 300 μM).
(C) LIP was evaluated as the fold increase of calcein fluorescence after
administration of 100 μM SIH, compared with before. Statistical significance
was calculated using one-way ANOVA followed by Bonferroni post hoc test;
*P<0.05, **P<0.01.
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in our cell system the elevation of mitochondrial calcium content
observed byRistow et al. (2000) does not activate OXPHOS andATP
production but, instead, might synergistically contribute to increase
the oxidative stress level. In fact, it has been reported that silencing of
mitochondrial calcium uniporter (MCU) and consequent reduction of
mitochondrial Ca2+ entry plays a protective role in HeLa cells and
in cerebellar granule neurons by decreasing the susceptibility to
oxidative stress conditions (Liao et al., 2015).
Our results are closer to those of Navarro et al. (2011) and
strongly suggest that both high and low levels of frataxin induce
oxidative stress. We also find no amelioration of the phenotype as a
consequence of overexpression, as deduced by Runko et al. (2008).
On the contrary, the increase of LIP not only promotes ROS
production, but might also alter other intracellular pathways that
depend on cellular iron content, as previously suggested (Chen et al.,
2016b), thus contributing to cellular toxicity. Neuronal cells, which
are affected in FRDA, are indeedmore susceptible to oxidative insults
and other stressful conditions (Pelizzoni et al., 2011).
Our results might be important for the design of therapeutic
strategies. Gene therapy is one of the most promising approaches
for curing this autosomal disease, which is caused by loss of
function as a consequence of partial silencing of the FXN gene.
However, the traditional method of randomly integrating an
exogenous, therapeutic FXN gene in the genome to restore protein
levels could potentially backfire because of the risk of insertional
oncogenesis (Hacein-Bey-Abina et al., 2008, 2010). In this regard,
the development of non-integrating viral vectors, such as adeno-
associated viruses (AAVs), has greatly improved the safety of
gene therapy. This approach has been used successfully with
remarkable results in two conditional mouse models that mimic
the cardiomyopathy and neuronal dysfunction of FRDA (Gérard
et al., 2014; Perdomini et al., 2014). After AAV delivery, frataxin
levels were increased in the relevant tissues, and both mouse
models showed increased life expectancy and a great reduction in
FRDA-associated phenotypes (Gérard et al., 2014; Perdomini
et al., 2014). Both viral approaches, however, take advantage of a
human exogenous FXN gene under the control of strong promoters
that induce overexpression of the therapeutic genes. Although the
mouse models showed great improvements, the lack of a tight
control on the levels of expression could generate the effects
detailed in the present study, with unknown long-term consequences
for patients treated this way. Recent studies have taken advantage of
the new CRISPR gene editing approach to produce the desired gene
correction (Ouellet et al., 2017). As an alternative, gene correction of
the endogenousFXN gene by reduction of the GAA expansion seems
to be preferable. This strategy has the advantage that frataxin levels
would be restored to physiological levels. It is, however, essential for
these studies to determine the effects of different levels of frataxin.
Finally, our conclusions strongly support the view of frataxin as a
regulator. Frataxin seems to function as the green light that senses
the effector iron concentration and allows cluster formation only
when sufficient concentrations of acceptors are available (Prischi
et al., 2010). So far, this model has been supported fully by
independent lines of evidence. We have also recently demonstrated
that another protein of the isc operon, YfhJ (also called IscX), which
is present almost exclusively in prokaryotes, modulates the effect of
frataxin in bacteria and blocks its inhibitory power as a function of
iron concentrations (Pastore et al., 2006). In eukaryotes, the
desulfurase is inactivated, and frataxin acts as an activator of the
same process according to an adaptation program that is often
observed between prokaryotes and eukaryotes. This evidence,
together with what we have reported in the present study, strongly
supports the view that frataxin is a regulator for which levels must be
tightly controlled and fine-tuned to the concentrations of iron and
cluster acceptors at any time point, with any imbalance leading to
oxidative stress and toxicity.
Fig. 5. In cell IRmeasurements. (A) Difference spectra of HEK293-cFXN cells
after removal of tetracycline (tet). (B) Second derivative of absorbance from
spectra normalized to the 1545 cm−1 band. (C) Time evolution of absorption
variation at 2922 cm−1 after removal of tetracycline. Bars represent the s.d.
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MATERIALS AND METHODS
Experimental outline
All measurements were carried out using the same experimental set-up.
Expression or overexpression of frataxin was obtained by culturing HEK-
cFXN cells in the presence of 10 or 100 ng ml−1 tetracycline. Experiments
designed to monitor the effects of the reduction of frataxin levels over time
were performed by culturing cells in the presence of 10 ng ml−1 tetracycline,
followed by removal of the antibiotic from the medium. Measurements were
carried out in each experiment at specific time points (2, 4, 6 and 8 days after
turning off cFXN expression).
Cell culture
Cell culture media and reagents, if not otherwise stated, were from Thermo
Fisher Scientific (Waltham, MA, USA). Wild-type HEK293 and HEK-cFXN
cells were cultured in Dulbecco’s modified Eagle’s medium, supplemented
with 10% tetracycline-free fetal bovine serum (FBS; Clontech, Takara),
10 mM sodium pyruvate, 2 mM L-glutamine, 50 U ml−1 penicillin and
50 µg ml−1 streptomycin and 2% (v/v) non-essential amino acids (NEAAs),
and kept at 37°C in humidified air enriched with 5% CO2. The culture
medium for HEK-cFXN cells was supplemented with 100 µg ml−1
hygromycin B, 15 µg ml−1 blasticidin, 0.4 µg ml−1 puromycin and varying
concentrations of tetracycline (Sigma-Aldrich), depending on the desired level
of frataxin induction (0, 10 or 100 ng ml−1).
Western blots
Cell samples were collected, pelleted by centrifugation and resuspended in
0.01 M sodium EDTA, 0.2% SDS and 2% NP40 in PBS, with protease
inhibitors (chymostatin, leupeptin, antipain and pepstatin 1:1000). Samples
were lysed for 30 min at 4°Cwith shaking, centrifuged for 10 min at 13,000 g
to remove the pellet, and the protein concentration in the supernatant was
measured using Pierce BCA assay (Thermo Fisher Scientific). Proteins (15 or
30 µg) were denatured for 5 min at 95°C in Laemmli sample buffer and
subjected to SDS-PAGE using 12.5% polyacrylamide gels (Life
Technologies). Samples were then transferred to a nitrocellulose membrane
(0.45 μm pore size; GE Healthcare Lifescience). After 1 h blocking with
TBS, 0.1% Tween-20 (Promega) and 1% milk, the membranes were
incubated overnight at 4°C with primary antibodies. Membranes were then
washedwith TBS and 0.1%Tween and incubated at room temperature for 1 h
with either goat anti-mouse or anti-rabbit secondary antibody (Bio-Rad),
depending on the primary antibody. The reaction was carried out with
secondary horseradish peroxidase conjugates and enhanced chemiluminescence
detection (Pierce Supersignal). Immunoblot bands were analyzed by Chemidoc
Touch Imaging System (Bio-Rad). Calnexin was used to normalize values.
During the project,we used the followingprimaryantibodies:mouse anti-FLAG
M2 antibody (1:10,000 dilution; F1804, Sigma-Aldrich), rabbit anti-GAPDH
(1:5000 dilution; 2118S, Cell Signaling Technologies), mouse anti-Tom20
(1:5000 dilution; 612278, BD Biosciences), anti-frataxin (1:3000 dilution;
kindly gifted by Dr F. Taroni, from Carlo Besta Neurological Institute, Milan)
and anti-calnexin (1:2500 dilution; BD Biosciences).
Aconitase assay
Whole-cell aconitase enzymatic activities were measured
spectrophotometrically using an aconitase enzyme activity kit (Abcam;
ab109712) following the manufacturer’s guidelines. Briefly, 50 μg of total
protein from whole-cell lysates was resuspended in aconitase preservation
buffer and loaded on a 96-well microplate. Equal amounts of the substrate
isocitrate and manganese were added to all wells, and the absorbance at
240 nm was recorded every 20 s for 30 min. The catalytic activity was
measure by the rate of formation of cis-aconitate as detected by the increase
in absorbance between 10 and 20 min (two time points between which the
rate is increasing linearly for all samples). The change in absorbance per
minute was converted to units per microgram (specific activity), i.e. the
activity of the enzyme per microgram of total protein expressed as
millimoles per minute per microgram.
Seahorse mitochondrial stress test
HEK293 cells and HEK-cFXN cells were plated into Seahorse 96-well XF
cell culture microplates (cat. no. 101085-004) at a density of 4×104 cells per
well using medium supplemented with the relevant antibiotics and different
concentrations of tetracycline (10 and 100 ng ml−1). Cells were left
overnight at 37°C in humidified air supplemented with 5% CO2. The next
day, the medium was changed to XF Base Medium (cat no. 102353-100)
supplemented with 1 mM pyruvate, 2 mM Glutamax and 10 mM glucose
(pH of the medium was adjusted to 7.4 using 1 M NaOH). Cells were then
incubated for 1 h at 37°C in a CO2-free incubator. The XF Cell Mito Stress
Test (cat no. 103015-100) was carried out by loading the XF 96
Extracellular Flux assay sensor cartridge with oligomycin (final well
concentration 1 µM), FCCP (final well concentration 0.25 µM) and
rotenone/antimycin A (final well concentration 0.5 µM). Readings were
normalized against the total protein content of each sample, and each
reading was reported as the ratio to the measurement at day 8 (without
tetracycline). Statistical significance was tested using one-way ANOVA and
Dunnett’s post hoc test (**P<0.01; ****P<0.0001).
Fluorescence microscopy measurements
For ROS and LIP measurements, tetracycline (10 or 100 ng ml−1) was
removed from the medium at the indicated number of days, and the cells
were plated on 96-well plates 48 h before fluorescence microscopy
measurements. Dye loading and fluorescence analyses were performed
in Krebs Ringer Hepes buffer (KRH; mM: 5 KCl, 125 NaCl, 2 CaCl2,
1.2 MgSO4, 1.2 KH2PO4, 6 glucose and 20 Hepes, pH 7.4) at 37°C.
Cells were loaded with CellROX Orange Reagent (5 μM, 30 min; Thermo
Fisher Scientific) and with calcein AM (0.25 μM, 10 min; Thermo Fisher
Scientific) for ROS and LIP measurements, respectively. In particular, for
LIP analysis, the fluorescence was measured before and 10 min after
incubation with 100 μM salicylaldehyde isonicotinoyl hydrazone (SIH), a
cell-permeant iron chelator, according to Kakhlon and Cabantchik (2002).
Nuclear staining, necessary for image acquisition and analysis, was
performed with Hoechst 33342 for 10 min at a final concentration of
10 µg ml−1. Images were acquired with an automated epifluorescent
inverted microscope (Array Scan XTI platform; Thermo Fisher Scientific).
Statistical significance was tested using one-way ANOVA followed by
either Dunnett’s post hoc test for ROS or Bonferroni’s post hoc test for LIP
analyses, respectively; *P<0.05; **P<0.01.
In cell IR
Cells were grown on 25 mm, 1-mm-thick, CaF2 optical windows
(Crystran, UK) to give extended adherent layers. The sample holder for
Fourier-transform infrared spectroscopy imaging on live cells is based on a
sandwich design, with two optical windows separated by a spacer. The
window with adherent cells is placed in the holder before being moved to
the IR microscope for the measurement. The sample temperature is set at
37°C by connection to a circulating water bath (Lauda, AT).
IR measurements were performed on a Bruker Vertex 80v interferometer
(Bruker Optics, D) connected to a Bruker Hyperion 3000 IR microscope
with a 64×64 pixel FPA MCT detector. A Ge-multilayer KBr beamsplitter
and the internal globar lamp were used to measure in the mid-IR spectral
region. An extended monolayer of cells was selected for the measurement
using the visible optics of the microscope. The background measurement
was performed on a region of the sample where only medium was present.
Two hundred and fifty-six scans were used for the background and 128 for
the sample. Scans were run in double-sided forward–backward acquisition
mode at a scan rate of 2.5 kHz and 4 cm−1 resolution. Single channel spectra
were obtained by performing a Fourier transform of the interferogram after
apodization with a Blackman–Harris 3-term function, using a zero-filling
factor of two and a Mertz phase correction. Data were plotted as absorbance
spectra. All the pixels of each spectral hypercubewere averaged to obtain the
spectrum of a cell layer. Samples were run in triplicate except for day 6,
which was run in duplicate.
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